Temporary ovarian suppression with goserelin and ovarian function protection in patients with breast cancer undergoing chemotherapy

Journal of Clinical Oncology

Volumn 29, Issue 24, 2011, Pages 3339-3340

  Del Mastro, Lucia ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GOSERELIN; PACLITAXEL;

AMENORRHEA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; HUMAN; LETTER; MENSTRUAL CYCLE; OVARY FUNCTION; OVULATION INHIBITION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; GOSERELIN; HUMANS; OVARY;

EID: 80051960510     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.9942     Document Type: Letter

References (5)

1. Gerber B., Von Minckwitz G., Stehle H., et al: Effect of luteinizing hormonereleasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: The GBG 37 ZORO study. J Clin Oncol 29:2334-2341, 2011
2. Fornier M.N., Modi S., Panageas K.S., et al: Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 104:1575-1579, 2005
3. Ganz P.A., Land S.R., Geyer C.E. Jr, et al: Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol 29:1110-1116, 2011
4. Petrek J.A., Naughton M.J., Case L.D., et al: Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: A prospective study. J Clin Oncol 24:1045-1051, 2006
5. World Health Organization: Research on the menopause: WHO Technical Report Series, no. 670. Geneva, Switzerland, 1981